Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GZMB | P10144 | 18/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 2/20 | 0.63 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21186382 | 0.91 | GZMB (0.84) | GZMBCASP1CASP3CASP8ACE | |
| SCHEMBL20099118 | 0.89 | GZMB (0.79) | GZMBCASP1CASP3CASP8ACE | |
| SCHEMBL21186451 | 0.87 | GZMB (0.77) | GZMBCASP3CASP8ACEACE2 | |
| SCHEMBL5917007 | 0.87 | GZMB (0.77) | GZMBCASP3CASP8ACEACE2 | |
| SCHEMBL5917002 | 0.87 | GZMB (0.77) | GZMBCASP3CASP8ACEACE2 | |
| SCHEMBL21186268 | 0.85 | GZMB (0.74) | GZMBCASP3 | |
| SCHEMBL5917113 | 0.84 | GZMB (0.72) | GZMBACEACE2 | |
| SCHEMBL5917103 | 0.84 | GZMB (0.72) | GZMBACEACE2 | |
| SCHEMBL21274616 | 0.83 | GZMB (0.78) | GZMBCASP3CASP8ACEACE2 | |
| SCHEMBL21186353 | 0.83 | GZMB (0.70) | GZMBCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338588-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | GZMB 1/4885CASP1 317/4885CASP3 428/4885 |
| US-20230338588-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | GZMB 1/4885CASP1 317/4885CASP3 428/4885 |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | GZMB 1/4885CASP1 317/4885CASP3 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.